WOONSOCKET, R.I., Nov. 18, 2025 /PRNewswire/ -- Aetna, a CVS Health® company (NYSE: CVS), is launching a market-leading generative AI-powered conversational experience in its digital channels that will simplify health care, allowing members to quickly and easily navigate their benefits for a personalized experience.
This represents a paradigm shift, as Aetna continues to transition from the industry's traditional transactional experience to a consumer health experience. Unlike other industry alternatives where conversational AI is relegated to a chat window, Aetna is embedding generative AI throughout its end-to-end digital experience.
The embedded approach ensures the Aetna assistant synthesizes all relevant information for the member. It will deliver immediate, easy-to-digest answers for the user, eliminating the need to weed through links or complex content. More specifically, members won't need to use technical healthcare terminology, such as "prior authorization" or "claims" to get answers, but instead can use plain language and receive a response that is personalized, understandable and visually dynamic.
Nathan Frank, SVP and Aetna's Chief Digital and Technology officer stated, "At Aetna, we are constantly innovating, leveraging tools like generative AI, to provide a personalized experience and help our members navigate healthcare in a new way. This capability will complement all the important human interactions our members already have with Aetna clinicians, care managers, advocates and support teams."
Key differentiators and capabilities include:
"We're making it easy to meet members where they are – both in their journey and their knowledge of health care," Frank said. "Our personalized approach offers a contextual understanding of a member's unique journey and revolutionizes how Aetna members interact with their health care."
This new capability initially launched to a beta population in October, and access will be expanded throughout 2025 and the first half of 2026. These near-term enhancements will include:
Explore a demo of Aetna's Next Generation AI Conversational Navigation
About Aetna
Aetna, a CVS Health business, serves an estimated 37 million people with information and resources to help them make better informed decisions about their health care. Aetna offers a broad range of traditional, voluntary and consumer-directed health insurance products and related services, including medical, pharmacy, dental and behavioral health plans, and medical management capabilities, Medicaid health care management services, workers' compensation administrative services and health information technology products and services. Aetna's customers include employer groups, individuals, college students, part-time and hourly workers, health plans, health care professionals, governmental units, government-sponsored plans, labor groups and expatriates. For more information, visit Aetna.com (e.g., clinical diagnoses, eligibility criteria, participation in a disease state management program).
About CVS Health
CVS Health is a leading health solutions company building a world of health around every consumer, wherever they are. As of September 30, 2025, the Company had approximately 9,000 retail pharmacy locations, more than 1,000 walk-in and primary care medical clinics and a leading pharmacy benefits manager with approximately 87 million plan members. The Company also serves an estimated more than 37 million people through traditional, voluntary and consumer-directed health insurance products and related services, including highly rated Medicare Advantage offerings and a leading standalone Medicare Part D prescription drug plan. The Company's integrated model uses personalized, technology driven services to connect people to simply better health, increasing access to quality care, delivering better outcomes, and lowering overall costs.
Media contact
Tara Burke
646-765-4971
This email address is being protected from spambots. You need JavaScript enabled to view it.

| Last Trade: | US$77.94 |
| Daily Change: | -0.47 -0.60 |
| Daily Volume: | 5,861,174 |
| Market Cap: | US$98.980B |
October 15, 2025 July 10, 2025 | |

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load